Bluejay Diagnostics Completes SYMON-II Enrollment, Boosts Cash Position for Symphony IL-6 Push
Event summary
- Completed enrollment of 750 patients in SYMON-II pivotal clinical study for Symphony IL-6 test.
- Cash position grew to $9.6 million by Q2 2026, up from $5.2 million at year-end 2025.
- Signed US manufacturing contract to mitigate supply-chain risks ahead of potential commercialization.
- Plans 510(k) submission for Symphony IL-6 test, currently an investigational device.
The big picture
Bluejay’s progress on SYMON-II and strengthened balance sheet position it for a potential regulatory milestone in sepsis diagnostics, a market where rapid, accurate triage tools are increasingly critical. The company’s ability to secure US manufacturing capacity underscores the strategic shift toward commercial readiness, though competition and reimbursement dynamics remain key hurdles.
What we're watching
- Regulatory Timeline
- Whether Bluejay can maintain momentum toward 510(k) submission after SYMON-II data analysis.
- Execution Risk
- The pace at which manufacturing readiness aligns with regulatory deadlines.
- Financial Runway
- How $9.6 million in cash will sustain operations through mid-2027 amid commercialization costs.